Advertisement


Volker Kunzmann, MD, on Advanced Pancreatic Cancer: Findings on nab-Paclitaxel/Gemcitabine and FOLFIRINOX

ESMO 2019 Congress

Advertisement

Volker Kunzmann, MD, of the University of Würzburg/Comprehensive Cancer Center Mainfranken, discusses the final results of a phase II multicenter trial on the conversion rate in locally advanced pancreatic cancer after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (Abstract 671O).



Related Videos

Prostate Cancer

Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses study findings which showed that cabazitaxel improved radiographic progression-free survival as well as overall survival in patients with metastatic castration-resistant prostate cancer (Abstract LBA13).

Prostate Cancer

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Olaparib/Enzalutamide/Abiraterone

Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the phase III PROfound trial results on the efficacy of olaparib in men with metastatic castration-resistant prostate cancer whose tumors harbor alterations in DNA damage response genes and who had disease progression on prior hormone therapy (Abstract LBA12).

Hepatobiliary Cancer

Angela Lamarca, MD, PhD, on Liver Metastases From Intrahepatic Cholangiocarcinoma

Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, discusses findings from a study that showed new staging criteria should be considered for patients diagnosed with liver metastases in the absence of other extrahepatic tumor spread (Abstract 731P).

Lung Cancer
Immunotherapy

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–small cell lung cancer, with improved overall survival vs chemotherapy (Abstract LBA4).

Gynecologic Cancers
Immunotherapy

Mansoor R. Mirza, MD, on Ovarian Cancer: Roundup of ESMO 2019 Top Abstracts

Mansoor R. Mirza, MD, of Copenhagen University Hospital, offers his perspective on three studies presented in the Presidential Symposium: the PRIMA/ENGOT-OV26/ GOG-3012 trial (niraparib for newly diagnosed advanced disease); the PAOLA-1/ENGOT-ov25 trial (olaparib plus bevacizumab maintenance therapy in newly diagnosed advanced disease); and the VELIA/COG-3005 study (integrating veliparib with front-line chemotherapy and maintenance therapy) (Abstracts LBA 1–4).

Advertisement

Advertisement




Advertisement